Supplementary Material

Association between respiratory disease pathogens in calves near feedlot arrival with treatment for bovine respiratory disease and subsequent antimicrobial resistance status

Jennifer N. Abi Younes¹, John R. Campbell¹, Sheryl P. Gow², Amelia R. Woolums³, Cheryl L. Waldner^{1*}

¹Department of Large Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada

²Canadian Integrated Program for Antimicrobial Resistance Surveillance, Public Health Agency of Canada, Saskatoon, SK, Canada

³Department of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS, United States

* Correspondence: Cheryl L. Waldner <u>cheryl.walder@usask.ca</u>

1 Supplementary Tables

Table S0. Bovine respiratory disease clinical scoring system used to identify calves eligible for first treatment. Adapted from Step *et al.* (24).

BRD C	BRD Clinical Scoring System – Reference List					
Score	BRD Code	Key Clinical Signs (*one or more signs are observed)	Occasional Clinical Signs (*may also be observed)			
0	Normal	Clinically normal animal				
1	Mild BRD	 Mildly ↑ respiratory rate Mild – moderate gauntness Quiet when observed from afar, but becomes alert when sees a human Shallow or dry cough 	 Nasal discharge (clear, cloudy, white, or yellow) 			

BRD C	BRD Clinical Scoring System – Reference List					
Score	BRD Code	Key Clinical Signs (*one or more signs are observed)	Occasional Clinical Signs (*may also be observed)			
2	Moderate BRD	 Mild or moderate depression lethargic, but may become alert when approached lower than normal head carriage "hiding" behavior Mild – moderate muscle weakness droopy ears slow stepping or mild incoordination Coughing repeatedly Breathing with slightly ↑ abdominal effort Moderate gauntness 	 ↑ Respiratory rate • Nasal discharge (clear, cloudy, white, or yellow) 			
3	Severe BRD	 Severe depression or weakness when approached: does not become alert, low head carriage maintained, does not move away cross stepping Repeated deep cough Marked respiratory effort open mouth breathing or panting moderate – marked ↑ abdominal effort 	 ↑ Respiratory rate Nasal discharge (clear, cloudy, white, or yellow) Moderate – extreme gauntness 			
4	Moribund (near death)	 Down, does not rise when approached or stimulated Standing, but does not move unless directly stimulated very weak: drags feet, sways, stumbles, falls Eyes very sunken, abdomen very tucked up 	• Any signs described for scores 1, 2, or 3			

BRD Case Definition			
BRD Score	Criteria		
1-2	• AND a rectal temperature $\geq 40 ^{\circ}\text{C}$		
≥ 3	 Regardless of rectal temperature With <u>NO</u> other obvious signs of disease (e.g., lameness, diarrhea, swollen limbs, etc.) 		

Table S1. Overview of statistical analyses for calves sampled near 36DOF for all culture and susceptibility (C/S) test results considered associated with C/S results for samples collected at 1DOF and 13DOF for individual calf-level, pen-level, and contextual analysis.

	Individual outcomes & risk factors	Pen-level outcomes & risk factors
Risk period for outcome of interest:	Outcome DNP C/S - Calf status 36DOF	Outcome DNP C/S - Pen results 36DOF
36DOF	Individual calf results from C/S at 1DOF	Pen results from calf C/S at 1DOF
36DOF	Individual calf results from C/S at 13DOF	Pen results from calf C/S at 13DOF

Culture and susceptibility (C/S) results considered:

• recovery of *M. haemolytica*, *P. multocida*, or *H. somni*

· co-isolation of two or more bacteria

· recovery of any BRD bacteria with: any AMR, macrolide resistance, or tetracycline resistance

Table S2. For calves sampled near 36DOF, associations between culture and susceptibility (C/S) results for calves at 1DOF and likelihood of subsequent C/S results near 36DOF. n=309 calves (tag identification not available for one calf at 1DOF). Analysis adjusted for year and injectable metaphylaxis administered and accounted for clustering by pen cohort.

			95%	ό CI	
Risk Factor: Culture Positive at 1DOF	Outcome: C/S result near 36DOF	OR	Lower	Upper	<i>P</i> -value
M. haemolytica	M. haemolytica	1.0	0.6	1.8	0.96
P. multocida	P. multocida	2.0	1.1	3.7	0.02
H. somni	H. somni	0.6	0.2	1.4	0.23
Any bacteria with AMR	Any bacteria with AMR	1.2	0.3	4.3	0.83
Any bacteria with macrolide resistance*	Any bacteria with macrolide resistance		Not e	stimable	
Any bacteria with tetracycline resistance**	Any bacteria with tetracycline resistance	16	2.4	∞	0.008

*Zero calves sampled near 36DOF had bacteria with macrolide resistance recovered at 1DOF.

**Exact logistic regression equation (SAS® version 9.4, Cary, NC, USA).

Table S3. For calves sampled near 36DOF, associations between culture and susceptibility (C/S) for calves at 13DOF and likelihood of subsequent C/S at 36DOF. Analysis adjusted for year and injectable metaphylaxis administered and accounted for clustering by pen cohort. AST data were not available for one calf at time point 3 (pen 16); n=309 calves for AMR analyses (N=16 pens).

			95%	6 CI	
Risk Factor: Culture Positive at 13DOF	Outcome: C/S result near 36DOF	OR	Lower	Upper	<i>P</i> -value
M. haemolytica	M. haemolytica	1.2	0.7	1.9	0.48
P. multocida	P. multocida	6.8	3.1	15	<0.001
H. somni	H. somni	1.0	0.3	3.4	0.97
Any bacteria with AMR	Any bacteria with AMR	1.9	0.8	4.2	0.13
Any bacteria with macrolide resistance*	Any bacteria with macrolide resistance	1.2	0.5	2.7	0.62
Any bacteria with tetracycline resistance	Any bacteria with tetracycline resistance	3.1	0.9	11	0.08

*Unconditional GEE reported as zero calves sampled near 36DOF from year 2021/oxytetracycline cohorts had bacteria with macrolide resistance recovered.

Table S4. For calves sampled near 36DOF, associations between culture and susceptibility (C/S) results at 36DOF given pen-level prevalence of C/S results at 1DOF and 13DOF. Analysis adjusted for year and metaphylaxis and accounted for clustering by pen cohort. n=1,599 calves at 1DOF and 1,596 calves at 13DOF (N=16 pens) (SAS® version 9.4, Cary, NC, USA).

			95%	% CI	
Risk Factor: Pen-level C/S Prevalence	Outcome Pen Probability	OR	Lower	Upper	<i>P</i> -value
Increase in prevalence at 1DOF	C/S at 36DOF				
M. haemolytica (5%)	M. haemolytica	1.0	0.9	1.2	0.53
P. multocida (5%)	P. multocida	1.0	0.9	1.0	0.39
H. somni (5%)	H. somni	1.0	0.9	1.1	0.91
Tetracycline resistance (5%)	Tetracycline resistance	1.5	1.2	1.9	0.0007
Macrolide resistance (5%)*	Macrolide resistance	8.8	0.8	103	0.08
Any AMR (5%)	Any AMR	1.0	0.6	1.8	0.92
Increase in prevalence at 13DOF	C/S at 36DOF				
M. haemolytica (5%)	M. haemolytica	1.0	0.9	1.0	0.23
P. multocida (5%)	P. multocida	1.2	1.2	1.3	<0.0001
H. somni (5%)	H. somni	1.0	0.8	1.3	0.93
Tetracycline resistance (5%)	Tetracycline resistance	1.0	1.0	1.1	0.04
Macrolide resistance (5%)*	Macrolide resistance	1.2	1.1	1.3	<0.0001
Any AMR (5%)	Any AMR	1.0	1.0	1.1	0.01

*Unconditional GEE reported as zero calves sampled near 36DOF from year 2021/oxytetracycline cohorts had bacteria with macrolide resistance recovered.

Table S5. Summary of associations between culture and susceptibility (C/S) results at 1DOF and 13DOF and subsequent C/S for calves at 36DOF.

Individual calf level models		
Predictor	Outcome	Significant risk factors
C/S result at 1DOF	C/S result at 36DOF	P. multocida, tetracycline resistance
C/S result at 13DOF	C/S result at 36DOF	P. multocida
Pen-level data		
Risk factor: Pen-level C/S prevalence	Outcome	Significant risk factors
Pen prevalence at 1DOF	C/S result at 36DOF	Tetracycline
Pen prevalence at 13DOF	C/S result at 36DOF	<i>P. multocida,</i> any AMR, macrolide resistance, or tetracycline resistance